These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15932152)

  • 1. [Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
    Minushkin ON; Maslovskiĭ LV; Anikina NIu; Shuleshova AG
    Eksp Klin Gastroenterol; 2005; (2):29-35. PubMed ID: 15932152
    [No Abstract]   [Full Text] [Related]  

  • 2. [Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].
    Khavkin AI; Zhikhareva NS; Rachkova NS; Babaian ML; Volynets GV; Khanakaeva ZK
    Eksp Klin Gastroenterol; 2004; (2):53-6. PubMed ID: 15462323
    [No Abstract]   [Full Text] [Related]  

  • 3. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
    Lim PW; Goh KL
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral cavity manifestations of gastroesophageal reflux disease].
    Maev IV; Barer GM; Busarova GA; Pustovoĭt EV; Polikanova EN; Burkov SG; Gurenev GL
    Klin Med (Mosk); 2005; 83(11):33-8. PubMed ID: 16404937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Some comparative aspects of treating the gastroesophageal reflux disease eradication].
    Minushkin ON; Maslovskiĭ LV; Anikina NIu
    Eksp Klin Gastroenterol; 2004; (3):45-8, 104. PubMed ID: 15560401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
    Miner P; Orr W; Filippone J; Jokubaitis L; Sloan S
    Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A; Breiter J; Perdomo C; Barth J
    Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
    Maev IV; Kucheriavyĭ IuA; Danilin MS
    Eksp Klin Gastroenterol; 2003; (5):10-2, 192. PubMed ID: 14621603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
    Kahrilas PJ; Miner P; Johanson J; Mao L; Jokubaitis L; Sloan S
    Dig Dis Sci; 2005 Nov; 50(11):2009-18. PubMed ID: 16240208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
    Maev IV; Balashova NN; Busarova GA
    Klin Med (Mosk); 2003; 81(9):54-9. PubMed ID: 14598594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rabeprazole once daily for acid-related disorders.
    Lanza F; Bardhan KD; Perdomo C; Niecestro R; Barth J
    Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabeprazole.
    Med Lett Drugs Ther; 1999 Nov; 41(1066):110-2. PubMed ID: 10987010
    [No Abstract]   [Full Text] [Related]  

  • 15. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A; Wruble LD; Humphries TJ
    Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of non-erosive minimal esophageal lesions in gastro-esophageal reflux disorder.
    Hong SP; Park PW; Hwang SG; Ko KH; Kwak SY; Kim SH; Kwon KS; Shin YW; Ryu JK; Ryu KH; Park SJ; Won WH; Yoo HM; Bae HM; Park MJ; Woo YK; Kim KC; Kim KH; Na SH; Kim JW
    Korean J Intern Med; 2004 Jun; 19(2):93-8. PubMed ID: 15366639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety profile of pariet clinical use (a literature review)].
    Sheptulin AA
    Voen Med Zh; 2001 May; 322(5):35-40. PubMed ID: 11550328
    [No Abstract]   [Full Text] [Related]  

  • 18. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
    Caos A; Moskovitz M; Dayal Y; Perdomo C; Niecestro R; Barth J
    Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.
    Damiano A; Siddique R; Xu X; Johanson J; Sloan S
    Dig Dis Sci; 2003 Apr; 48(4):657-62. PubMed ID: 12741452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
    Park SH
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.